It c has shown great potential in the study of acute myeloid leukemia and is currently being developed as a cancer therapy based on the p53 reactivation mechanism.391 In preclinical studies, DS-3032 has been found to selectively and dose-dependently induce apoptosis in neuroblastoma cells with wild-type TP53, while having no effect on TP53-mutated Kelly cells. Here, TP53 is linked to cancer.